CooperCompanies Shares Fall 13.9% on Weak Q2, CooperSurgical Retention

EarningsCorporate ActionAnalyst
โดย Yahoo Finance·US·Read original
Summary · why it matters

CooperCompanies shares fell 13.9% after the medical device company reported weak second-quarter results and decided to retain its CooperSurgical business. Revenue came in at $1.07 billion, flat year-over-year and below analyst estimates of $1.10 billion, while organic revenue grew just 1%; adjusted earnings of $1.15 per share edged past the $1.12 consensus as operating margins expanded to 20.8% from 16.6% a year ago. Chief Executive Officer Al White said proactive U.S. channel inventory reductions at CooperVision weighed heavily on the top line and will continue to be a drag into the next quarter, prompting management to lower full-year revenue guidance to a midpoint of $4.24 billion from $4.30 billion and cut its full-year adjusted EPS outlook to $4.53 at the midpoint. The company also concluded a strategic review initiated in December 2025, with its board unanimously deciding to retain the CooperSurgical business after assessing acquisition proposals, citing valuation disconnects linked to incoming non-hormonal IUD competition and recent litigation settlements, and expanded its share repurchase authorization to $3 billion. William Blair downgraded CooperCompanies to Market Perform from Outperform following the report.

Impact on stocks 2

Aging Population▼ · 2 stocks
The Cooper Companies, Inc
COO
▼ NegativeCapitalCompetitionrelevance

Weak Q2 revenue ($1.07B, flat YoY, below estimates) and lowered full-year revenue/EPS guidance, plus a William Blair downgrade.

Off-coverage companies 1

William Blair & CompanyPrivate▼ Negative
Capitalrelevance

William Blair downgraded CooperCompanies to Market Perform from Outperform following the weak report.

© 2026 MarketDXNews